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Abstract
TGF-b Inducible Early Gene-1 (TIEG1) is a Kru ¨ppel-like transcription factor (KLF10) that was originally cloned from human
osteoblasts as an early response gene to TGF-b treatment. As reported previously, TIEG1
2/2 mice have decreased cortical
bone thickness and vertebral bone volume and have increased spacing between the trabeculae in the femoral head relative
to wildtype controls. Here, we have investigated the role of TIEG1 in osteoclasts to further determine their potential role in
mediating this phenotype. We have found that TIEG1
2/2 osteoclast precursors differentiated more slowly compared to
wildtype precursors in vitro and high RANKL doses are able to overcome this defect. We also discovered that TIEG1
2/2
precursors exhibit defective RANKL-induced phosphorylation and accumulation of NFATc1 and the NFATc1 target gene DC-
STAMP. Higher RANKL concentrations reversed defective NFATc1 signaling and restored differentiation. After differentiation,
wildtype osteoclasts underwent apoptosis more quickly than TIEG1
2/2 osteoclasts. We observed increased AKT and MEK/
ERK signaling pathway activation in TIEG1
2/2 osteoclasts, consistent with the roles of these kinases in promoting osteoclast
survival. Adenoviral delivery of TIEG1 (AdTIEG1) to TIEG1
2/2 cells reversed the RANKL-induced NFATc1 signaling defect in
TIEG1
2/2 precursors and eliminated the differentiation and apoptosis defects. Suppression of TIEG1 with siRNA in wildtype
cells reduced differentiation and NFATc1 activation. Together, these data provide evidence that TIEG1 controls osteoclast
differentiation by reducing NFATc1 pathway activation and reduces osteoclast survival by suppressing AKT and MEK/ERK
signaling.
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Introduction
During osteoclast formation, RANKL and M-CSF activate
NFkB, c-Jun N-terminal kinase, ERK, and AKT [1,2,3,4,5,6].
These signaling pathways also modulate osteoclast survival in
response to RANKL and M-CSF. RANKL also activates or
induces the expression of transcriptional factors important for
osteoclastogenesis including c-Fos, MITF and NFATc1 [7,8,9].
NFATc1 is considered a master regulator of RANKL-induced
osteoclastogenesis since reduced expression of NFATc1 causes
defects in osteoclastogenesis in response to RANKL. NFATc1 is
regulated by the serine/threonine phosphatase calcineurin, which
is activated by intracellular Ca
2+. Dephosphorylation of NFATc1
at serine residues by calcineurin stimulates NFATc1 to translocate
into the nucleus [9]. A crucial gene target for NFATc1 in
osteoclast precursors is dendritic cell-specific transmembrane
protein (DC-STAMP), a ‘‘master fusion gene’’ for osteoclast
differentiation [10,11,12]. Several other cellular components such
as a disintegrin and metalloproteinase (ADAM) 8 and 12,
adenosine A1 receptors, CD200 receptor, CD36, CD63, E-
cadherin, filamin A, some integrins, some matrix metalloprotei-
nases, a subunit of the v-ATPase, and the intracellular phospha-
tases SHP1 and 2 have also been implicated in regulating
osteoclast fusion [13]. The mechanisms by which these diverse
proteins function remain mostly unresolved [13].
TGF-b Inducible Early Gene-1 (TIEG1) was originally cloned
from human osteoblasts as a primary response gene to TGF-b
treatment [14]. TIEG1 is a member of the Kru ¨ppel-like
transcription factor family (KLF10) which is expressed in
numerous tissues [15,16,17,18,19] and is involved in the
regulation of cell growth, differentiation and apoptosis
[20,21,22]. We have previously demonstrated that TIEG1
knockout mice (TIEG1
2/2) display a gender specific osteoporotic
bone phenotype [23,24]. Specifically, analysis of the distal femur
metaphysis revealed a 44% decrease in cancellous bone volume
(BV/TV) of congenic TIEG1
2/2 mice compared to wildtype
(WT) mice [24]. In this study, the number of osteoclasts in
TIEG1
2/2 mice remained unchanged from wildtype mice in spite
of the defective ability of osteoblasts to support osteoclast
differentiation [25]. Additionally, a recent study has demonstrated
that TIEG1
2/2 osteoblasts have increased expression of OPG
suggesting that osteoclast differentiation in these animals could be
impaired [26]. Because of this discrepancy, we examined
osteoclast precursor differentiation in TIEG1
2/2 bone marrow
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17522Figure 1. Lack of TIEG1 in osteoclast precursors delays osteoclast differentiation and apoptosis in vitro.A . WT and TIEG1
2/2 marrow
cells were cultured as described in the Methods section and subsequently fixed and stained for TRAP activity and chromatin condensation beginning
on day 3 or after feeding the cells with MCSF and RANKL for the indicated time in hours (h). These data are representative of three separate
experiments. B. Mean +/2 SD of viable osteoclasts over time. These data were obtained from four replicate wells (p,0.05) and are representative of
TIEG1 Regulates Osteoclast Differentiation
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e17522precursors. Here, we demonstrate that loss of TIEG1 reduces
NFATc1 activation and slows the rate at which osteoclasts
differentiate in vitro. Moreover, loss of TIEG1 in mature osteoclasts
reduces apoptosis and results in increased activation of pro-
survival AKT/NFkB and MEK/ERK signaling.
Results
Loss of TIEG1 Delays Osteoclast Differentiation in Vitro
We compared the ability of WT and TIEG1
2/2 marrow-
derived osteoclast precursors to differentiate in vitro into osteoclasts
when treated with M-CSF and RANKL (Figure 1). The results of
these studies revealed a significant delay in the ability of precursors
from TIEG1
2/2 marrow cells to differentiate compared to WT
precursors (Figure. 1A and B). To ensure that there were no
contaminating mesenchymal cells in our experiments which could
contribute to the observed differences in osteoclast differentiation,
we cultured the non-adherent cells from WT and TIEG1
2/2
marrow in the absence of MCSF. As expected, none of these non-
adherent cells survived in the absence of MCSF confirming that
the non-adherent cells from both WT and TIEG1
2/2 mice have
minimal, if any, mesenchymal cell contamination (data not
shown). During late stages of culture, the number of WT
osteoclasts decreased due to apoptosis (Figure 1C, D and E),
which is consistent with our previous report [27]. However,
osteoclasts lacking TIEG exhibited significantly less apoptosis than
WT osteoclasts. Because TIEG1 is known to suppress the
proliferation rates of several cell types [16,17,28], we next
investigated the impact of loss of TIEG1 expression on osteoclast
precursor proliferation. The proliferation rate of TIEG1
2/2
marrow cells was elevated in the presence of RANKL and MCSF
compared to WT cells (Figure 1F). To examine the numbers of
osteoclast precursors in the marrow, we analyzed the number of
granulocyte/macrophage colony forming units (CFU-GMs) and
found that there were significantly more colonies per well in the
TIEG1
2/2 marrow cultures relative to WT controls (Figure 1G).
TIEG1 Suppresses Survival Signaling While Promoting
NFATc1 Activation
AKT, MEK/ERK, and NFATc1 activation are required for
osteoclast differentiation [6,9,29]. Moreover AKT and MEK/
ERK activation are required for osteoclast survival [5,30]. We
compared activation of these pathways in osteoclast precursors
and mature osteoclasts between WT and TIEG1
2/2 marrow cells
(Figure 2). We observed that M-CSF induced higher phosphor-
ylation of AKT and MEK/ERK signaling in TIEG1
2/2
precursors and mature osteoclasts compared to WT cells
(Figure 2A). Phosphorylation of p38 and JNK did not differ
between WT and TIEG1
2/2 precursors and mature osteoclasts
(data not shown). However, increased activation of MEK/ERK
and AKT were not consistent with the reduced differentiation of
TIEG1
2/2 precursors. We therefore examined NFATc1 activa-
tion as this is the pivotal activation target of RANKL [9]. Unlike
AKT, MEK, and ERK, phosphorylation of NFATc1 negatively
influences activity as it is excluded from the nucleus when
phosphorylated [9]. On day 3, TIEG1
2/2 control precursors
exhibited increased phosphorylation, thus decreased activation, of
NFATc1 compared to WT cells (Figure 2A). Consistent with these
data, we also observed similar activation of phospho-NFATc1,
MEK/ERK and AKT in TIEG1
2/2 precursors and mature
osteoclasts from marrow derived cells from 16 month old mice
(data not shown). To verify differential activation of NFATc1
between the two genotypes, we next examined osteoclast
precursors for phospho- (Figure 2B) and total (Figure 2C) NFATc1
nuclear localization prior to and following 5 minutes of MCSF
and RANKL treatment. As expected, these data demonstrated a
decrease in phospho-NFATc1 nuclear localization in all cells
(Figure 2B). However, TIEG1
2/2 precursors exhibited increased
cytoplasmic staining for phospho-NFATc1 regardless of M-CSF
treatment compared to WT cells (Figure 2B). Quantitative
examination of total NFATc1 staining revealed that, in WT
precursors, the 5 minute MCSF and RANKL treatment led to
increased nuclear localization whereas there was less evidence of
nuclear localization in TIEG1
2/2 osteoclast precursors
(Figure 2C). We examined expression of genes that have been
implicated in osteoclast fusion and found that loss of TIEG1 in
pre-fusion day 3 precursors resulted in decreased DC-STAMP
expression compared to WT day 3 precursors (Figure 2D).
However, expression of other genes known to be involved in
osteoclast fusion were not similarly suppressed in TIEG1
2/2 day 3
precursors (Table S1).
Effects on Differentiation Due to Loss of TIEG1 Expression
are a Result of Defective RANKL Responses
The above observations suggested that altered RANKL
signaling could be the cause of the delay in TIEG1
2/2 osteoclast
precursor differentiation. To evaluate this possibility, we tested a
range of RANKL concentrations for their effects on differentia-
tion. We observed that treatment with 100 ng/ml RANKL
abolished the defect in osteoclast differentiation in TIEG1
2/2
precursors (Figure 3A). Examination of RANKL effects on
signaling pathway activation revealed that 100 ng/ml RANKL
also reduced the differences between WT and TIEG1
2/2
precursor signaling (Figure 3B). Specifically, we observed that
dephosphorylation of NFATc1 was increased in WT precursors in
the presence of 50 and 100 ng of RANKL when compared to
TIEG1
2/2 osteoclast precursors (Figure 3B). This observation was
also confirmed by localization of phospho- (Figure 3C) and total
(Figure 3D) NFATc1 which demonstrated that nuclear localization
of NFATc1 was restored following 100 ng/ml RANKL treatment.
These co-localization data revealed that increased phosphoryla-
tion of NFATc1 reduced nuclear localization of NFATc1 in
osteoclasts precursors from TIEG
2/2 mice in the presence of
100 ng RANKL (Figure 3B and C). Overall these observations
support the hypothesis that increased phosphorylation of the
NFATc1 pathway in TIEG1
2/2 osteoclast precursors is likely to
be the mechanism that leads to delayed osteoclast differentiation in
the absence of TIEG1 expression. Since cathepsin K is a marker of
three separate experiments. C. Image of TRAP and Hoechst stained osteoclasts on day 4. Viable osteoclasts are indicated with an arrow and apoptotic
osteoclasts are indicated with a star. These data are representative of three separate experiments. D. Mean +/2 SD of the number of apoptotic
osteoclasts on day 3 after feeding the cells with MCSF and RANKL for the indicated time in hours. Note that apoptosis is not observed until day 4
(24 h after feeding on day 3). E. The ratio of apoptotic osteoclasts to total number of osteoclasts is also presented as mean +/2 SD. These data were
obtained from four replicate wells. (p,0.05) and are representative of three separate experiments. F.M e a n+/2 SD of proliferation of WT and TIEG1
2/2
osteoclastprogenitors.WTandTIEG1
2/2non-adherent bonemarrowcellswereseededat1610
5 cells/wellin96-wellplatesandgrownat37uCfor3 h at
day 0, 1, 2 and 3 of differentiation. Proliferation was determined using an absorbance of 490 nm and the CellTiter 96H AQueous One Solution Assay kit.
These data were obtained from eight replicate wells (p,0.05) and are representative of three separate experiments. G. The mean +/2 SD of number of
colony forming units (CFU)-GM. These data are from three replicate wells (p,0.05) and are representative of three separate experiments.
doi:10.1371/journal.pone.0017522.g001
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PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17522Figure 2. Signaling pathway analysis following MCSF and RANKL treatment. A. Osteoclast precursors at day 3 and mature osteoclasts at
day 4 were serum-starved and treated with MCSF, RANKL or MCSF+RANKL as indicated for five minutes. Equal amounts of total protein were analyzed
by western blotting for the indicated phospho (p) or total (t) proteins. These data are representative of two separate experiments. For each
TIEG1 Regulates Osteoclast Differentiation
PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e17522osteoclast differentiation, we also examined the effect of loss of
TIEG1 on cathepsin K expression during the differentiation time
period (Figure 3E). We found that cathepsin-K expression was
reduced in TIEG1
2/2 osteoclast precursor cells when compared
to WT osteoclast precursors in the presence of MCSF and
RANKL (Figure 3E). In addition, we observed that WT cultures
treated with low doses of RANKL exhibited higher levels of
cathepsin K protein than TIEG1
2/2 cultures and increased
RANKL levels stimulated increased cathepsin K expression in late
stages of differentiation of TIEG1
2/2 precursors.
AdTIEG1 expression in TIEG1
2/2 OC precursors restores
differentiation and signaling
We examined whether TIEG1 restoration in vitro in osteoclast
precursors could restore the WT phenotype of TIEG1
2/2 cells.
We infected precursors from TIEG1
2/2 mice with a mouse
adenoviral TIEG1 (AdTIEG1) expression construct on day 2 at a
multiplicity of infection (MOI) of 25. Controls were empty vector
infected marrow cells from TIEG1
2/2 mice. Expression of
AdTIEG1 was determined by real time-PCR at days 3 and 4.
Infection with AdTIEG1 significantly increased TIEG1 expression
(Figure 4A). We next examined the influence of AdTIEG1 on
mature osteoclasts apoptosis and differentiation of TIEG1
2/2
precursors. We found that restoration of TIEG1 expression in
TIEG1
2/2 precursors resulted in increased apoptosis of mature
cells (Figure 4B). Examination of differentiation influences
revealed that adenoviral infected cultures differentiated ,35%
more when compared to vector infected cells (Figures 4C and 4D).
We therefore infected precursors from TIEG1
2/2 marrow as
above and examined signaling responses. AdTIEG1 expression
suppressed activation of the AKT and MEK/ERK survival
pathways (Figure 4E). Consistent with the differentiation data,
AdTIEG1 expression had a suppressive effect on the transient
NFATc1 phosphorylation in TIEG1
2/2 precursors. To confirm
effects on differentiation, we examined cathepsin K expression
responses. At both days 3 and 4, TIEG1 expression significantly
increased mRNA expression of cathepsin K (Figure 4F). Cathepsin
K protein levels were assessed 6 hours after feeding on Day 3 and
increase protein expression was also observed following AdTIEG1
infection (Figure 4G).
Suppression of TIEG1 inhibits differentiation and
increases NFATc1 phosphorylation
We used siRNA to block TIEG1 expression in WT cells to
determine if we could recapitulate the TIEG1
2/2 phenotype.
Both non-targeting siRNA and siTIEG1 were fluorescently tagged
to allow for an estimation of transfection efficiency. As shown in
Figure 5A, siTIEG1 suppressed TIEG1 expression to about 26%
relative to controls and the fluorescent tag indicated that a large
portion (estimated at about 70%) of the cells contained the
construct. Even this modest reduction in TIEG1 expression
resulted in significant biological impacts and mimicked the
TIEG1
2/2 phenotype. Specifically, suppression of TIEG1
expression significantly decreased osteoclast differentiation of
WT precursors (Figure 5B). Consistent with this, phosphorylation
of NFATc1 was elevated in WT precursor cells containing
siTIEG1 (Figure 5C) and cathepsin K protein expression was
suppressed (Figure 5D).
Effects of Loss of TIEG1 on Gene Expression
We performed real time-PCR to analyze genes associated with
osteoclastogenesis. We found a trend in that expression of c-fos,
PU1, and RANK, the receptor for RANKL, were mostly down-
regulated in TIEG1
2/2 cells compared to WT controls (Figure 6).
Expression of osteoclast inhibitory lectin (OCIL) was significantly
up-regulated in TIEG1
2/2 osteoclast lineage cells relative to those
from WT mice (Figure 6). Evaluation of the effects of loss of
TIEG1 on Bcl2 family members revealed no elevation of pro-
survival members including Bcl2 and no suppression of pro-
apoptosis family members (Table S2). Since we have previously
shown that overexpression of Bcl2 can rescue mature osteoclast
apoptosis [31], we examined the impact of AdTIEG infection on
levels of Bcl2 gene and protein expression. We observed that late
osteoclast TIEG1
2/2 precursors expressed detectable levels of
Bcl2 protein whereas WT precursors did not (Figure 7B). Infection
of TIEG1
2/2 precursors with AdTIEG suppressed Bcl2 mRNA
and protein levels (Figure 7A and B).
Discussion
To better understand the biological function of TIEG1 in
osteoclastogenesis, we have investigated the role of TIEG1 in
osteoclast precursor differentiation to determine if there is a defect
that is independent of osteoblast influences. Osteoclast precursors
isolated from female TIEG1
2/2 mice differentiated more slowly
and survived longer when compare to WT precursors. In bone, we
have previously published that there are increased numbers of
osteoblasts that exhibited an impaired ability to support osteoclast
differentiation [25]. Our observation reported here is that there is
likewise an impaired ability of osteoclast precursors lacking TIEG1
to fuse. These two observations would lead one to expect that
there would be a reduced number of osteoclasts in TIEG1
2/2
bones, which is not what was observed [23]. Longer culture of
osteoclasts indicated that there was a reduction in apoptosis in
TIEG1
2/2 mature osteoclasts, allowing these cells to survive
longer. This last observation suggests that the sustained number of
osteoclasts in TIEG1
2/2 bones is due to a reduction in osteoclast
apoptosis. Reductions in apoptosis likely compensate for the
impaired ability of TIEG1
2/2 osteoblasts to support OC
differentiation and reduced ability of TIEG1
2/2 precursors to
fuse and form multinucleated osteoclasts. We chose to examine
early osteoclast precursors to determine whether the defect in
differentiation was due to a reduction in the proliferative response
to cytokines and/or due to fewer early progenitor cells. Loss of
TIEG1 expression resulted in increased proliferation rates,
eliminating that as the cause of the differentiation defect. The
CFU assays indicate that there are significantly more early
progenitors in the TIEG1
2/2 marrow cultures also eliminating
this as a cause of the defect as well. However, this later observation
experiment, marrow cells from three mice were pooled and analyzed in three replicate wells. The data are presented as the mean +/2 SD from all
replicate wells. B. Confocal images of the effect of RANKL and MCSF treatment on phospho- NFATc1 and total NFATc1, respectively. These data are
representative of two separate experiments. C. Quantitative nuclear NFATc1 was calculated at T0 and T59 after RANKL and MCSF treatment.
Precursors were cultured with MCSF and RANKL as in Figure 1. On day 3, the cells were rinsed and serum starved for 1 hour prior to ether fixing (T0)
or 5 minutes (T59) of treatment with M-CSF and RANKL. These data are representative of two separate experiments and each experiment is analyzed
in three replicate wells. D. Loss of TIEG1 expression results in decreased DC-STAMP expression in pre-fusion day 3 precursors compared to WT day 3
precursors. These data are representative of two separate experiments. For each experiment, marrow cells from three mice were pooled and analyzed
in three replicate wells. The data are presented as the mean +/2 SD from all replicate wells.
doi:10.1371/journal.pone.0017522.g002
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2/2 osteoclast lineage cells results from defective RANKL responses. A. Mean number of
osteoclasts from WT and TIEG1
2/2 (KO) mouse marrow following 4 days of culture in the presence of 25 ng/ml MCSF and the indicated
concentrations of RANKL as outlined in the Methods section. Cells were stained and the number of osteoclasts quantitated as in Figure 1 (*p,0.05).
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The responses to restoration of TIEG1 in TIEG1
2/2 cells and
suppression of TIEG1 in WT cells confirm that the observed
impacts of loss of TIEG1 are osteoclast lineage cell-autonomous
defects and not simply the result of defects in osteoblast/osteoclast
cross-talk.
To better understand the mechanistic basis for the defects in
osteoclast differentiation and survival, we investigated the role of
TIEG1 in activation of pathways known to be involved in these
processes. We therefore examined osteoclast precursors for
evidence of altered activation of intracellular signaling components
downstream of M-CSF and RANKL. We observed that loss of
TIEG1 reduced cytokine-mediated activation of NFATc1, the
master regulator of osteoclast differentiation [9,32]. DC-STAMP
is required for osteoclast precursor fusion and is stimulated by
NFATc1 pathway activation [12]. Loss of TIEG1 also resulted in
decreased DC-STAMP expression, confirming that the defect in
NFATc1 activation is the probable cause of the defective osteoclast
differentiation in TIEG1
2/2 precursors. We discovered that this
defect in osteoclast differentiation is restored by increasing the
concentration of RANKL, suggesting that the defect likely resides
in RANKL signaling. Our findings therefore suggest that
increased TIEG1 expression mediates RANKL-dependent
NFATc1 signaling during osteoclast differentiation. To further
resolve this, we examined the gene expression levels of crucial
signaling pathway components required for osteoclast differenti-
ation including the MCSF receptor, c-fms, the RANKL receptor
RANK, and other differentiation-associated genes including
TRAFs 2, 3, 5, and 6, OSCAR, TREM2, DAP12, Syk, Fc
Receptor c, MITF, PTEN, and Phospholipase C c. Of all of these
signaling components, RANK was the sole gene whose expression
was suppressed in TIEG1
2/2 osteoclast precursors during the
interval in which differentiation was delayed and up-regulated
during the time period in which the TIEG1
2/2 precursors are
fusing. The hematopoietic transcription factor PU-1 is required for
osteoclast differentiation and function, at least in part, by up-
regulating RANK expression [33,34]. We observed that expres-
sion of PU-1 was reduced during the time of differentiation in
which TIEG1
2/2 precursors exhibit a delay in differentiation and
expression increased in TIEG1
2/2 cells as they fuse. RANK
signaling leads to increased c-fos expression, which elevates
NFATc1 expression and activation to promote osteoclast differ-
entiation [9]. During the time period in which osteoclast
differentiation is delayed in same cell line, c-fos gene expression
and NFATc-1 protein expression were both decreased in the
TIEG1
2/2 precursors compared to WT cells. This defect was
repaired later in differentiation when the TIEG1
2/2 precursors
were fusing. OCIL inhibits osteoclast differentiation by suppress-
ing c-Fos and NFATc1 activation [35,36]. OCIL levels were
elevated in TIEG1
2/2 precursors during the time of delay and
decreased during the period in which the cells were fusing.
NFATc1 gene expression was not altered when AdTIEG1 was
administered to TIEG1
2/2 precursors. Since NFATc1 auto-
amplifies during osteoclast differentiation, suppression of NFATc1
activation by OCIL may be the cause of the decrease in NFATc1
protein accumulation observed in the TIEG1
2/2 precursors. This
observation supports that expression of NFATc1 in osteoclasts is
not directly modulated by TIEG1, but may be due to
posttranslational and/or indirect effects such as those of OCIL.
The left panel of Figure 8 summarizes our conclusions of the
mechanisms by which TIEG1 supports osteoclast precursor fusion
leading to multinucleated osteoclasts.
Unexpectedly, MEK/ERK and AKT signaling were elevated in
the absence of TIEG1, which is the opposite of what one would
expect if these pathways were causing the defect in osteoclast
differentiation. We and others have documented that MEK/ERK
and AKT pathways are required to support osteoclast survival
[5,27,30,37,38,39]. We have documented that adenovirus medi-
ated expression of constitutively active AKT or MEK increases
survival [5,40]. These observations support that loss of TIEG1 on
the MEK/ERK and AKT pathways are integral to the observed
increased survival of osteoclasts. The observed increased activation
of MEK/ERK and AKT in spite of reduced osteoclast
differentiation is likely to be the mechanism by which loss of
TIEG1 expression results in reduced apoptosis (Figure 8, right
panel). Having eliminated TIEG1 regulation of gene expression of
upstream modulators such as PTEN, consideration must be taken
of the known functions of TIEG1 in other bone cells to resolve the
mechanism by which TIEG1 promotes osteoclast apoptosis. Our
data show that Bcl2 protein levels are higher in TIEG1
2/2
precursors without detectable changes in mRNA levels. These
data support altered translation and/or targeted degradation of
Bcl2 protein between the genotypes. The observation that
expression of TIEG1 in the TIEG1
2/2 precursors abrogated
Bcl2 protein indicates that this is a cell-autonomous effect of
TIEG1 in osteoclast precursors. In addition, it is believed that the
apoptosis of osteoclast precursors may be involved in the activation
of caspase-9 and that RANKL may promote their survival through
Bcl2-induced inhibition of caspase-9 activation [41]. Our findings
showed that treatment with RANKL (100 ng) at day 3
significantly increased caspase-9 activation in WT osteoclast
precursors when compare to TIEG1
2/2 precursors (Figure S1A)
suggesting that TIEG1 mediates RANKL-induced caspase-9
cleavage in osteoclasts. This observation is confirmed by
AdTIEG1 expression in TIEG1
2/2 precursors (Figure S1B).
Taken together, the findings reported here support that TIEG1
expression in osteoclast precursors accelerates osteoclast differen-
tiation and apoptosis. Rapid turnover of osteoclasts in vivo have
been observed [42]. This ability of vertebrates to rapidly alter bone
resorption allows for fine-tuning of release of calcium from bone.
Within the bone environment, osteoclast-mediated release of
calcium and osteoblast-mediated incorporation of calcium into
bone matrix act in concert to tightly control extracellular calcium
levels [43]. Both osteoclasts and osteoblasts respond to local
These data were obtained from three replicate wells (p,0.05) and are representative of three separate experiments. B Osteoclast precursors at day 3
and mature osteoclasts at day 4 were treated with the indicated concentration of RANKL and equal amounts of total protein were analyzed by
western blotting for the indicated phospho- or total proteins. These data are representative of two separate experiments. For each experiment,
marrow cells from three mice were pooled and analyzed in three replicate wells. C and D. Confocal images demonstrating the effect of RANKL on
phospho- NFATc1 (C) or total NFATc1 (D). Precursors were cultured with MCSF with or without RANKL as indicated. On day 3, cells were fixed and
stained with the indicated primary antibodies. These data are representative of two separate experiments and each experiment is analyzed in three
replicate wells. E and F. Time course expression of cathepsin K in WT and TIEG1
2/2 (KO) osteoclast precursors (day 3) and mature osteoclasts (day 4)
cultured in the presence of MSCF alone (E) or with the indicated concentration of RANKL (F). Precursors and mature osteoclasts were harvested and
cultured as in A for the indicated time. Equal protein from cell lysates were analyzed by western blotting for cathepsin K protein expression. These
data are representative of two separate experiments. For each experiment, marrow cells from three mice were pooled and analyzed in three replicate
wells.
doi:10.1371/journal.pone.0017522.g003
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PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e17522Figure 4. AdTIEG1 expression in TIEG1
2/2 OC precursors restores differentiation and signaling defects. A. TIEG1
2/2 precursor
osteoclasts were infected at day 2 with vector control (AdVec) or TIEG1 (AdTIEG) adenovirus (MOI=25) and TIEG expression was monitor by real time
PCR at day 3 and day 4. These data were obtained from three replicate wells and are represented as the mean +/2 SD (p,0.05). B. AdTIEG1
expression effects on osteoclast apoptosis. Osteoclast precursors were cultured as in A and apoptosis determined as in Figure 1D. Mean +/2 SD of
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osteoclasts, this response leads to decreased resorption [44].
Osteoblast responses to extracellular calcium, in contrast, promote
differentiation, survival, and matrix mineralization [45]. Thus,
tight control of extracellular calcium may be involved in coupling
bone resorption to subsequent bone formation. Rapid modulation
of circulating calcium is also a crucial need for organisms since
calcium has extensive impacts on most cells. This becomes
important in such circumstances as mobilization of calcium during
lactation. In breast cells during lactation, low calcium levels in the
circulation trigger secretion of Parathyroid Hormone Related
Peptide (PTHrP) to increase osteoclast differentiation and bone
resorption, which elevates circulating calcium levels for milk
production [46]. Once circulating calcium levels are elevated,
PTHrP production drops, and the rapid turnover of osteoclasts
insures that bone resorption will likewise cease. Our study supports
that expression of TIEG1 in osteoclast lineage cells is an integral
component of osteoclast turnover. In TIEG1
2/2 mice, in which
TIEG1 is missing in all cells, the defect in osteoblast-mediated
support of osteoclast differentiation likely mitigates the cell-
autonomous defects in the osteoclast lineage cells that suppress
mature osteoclast apoptosis. Testing this hypothesis will require
selective deletion of TIEG1 in osteoclast lineage cells, which is a
future direction of this project.
Materials and Methods
Ethics Statement
Description and characterization of TIEG1
2/2 mice have been
previously described [23,24]. In this study, 6–12 week old to 16
month old female congenic C57BL/6 WT and TIEG1
2/2
littermates were used. All animal research was conducted
according to guidelines provided by the National Institute of
Health and Institute of Laboratory Animal Resources, National
Research Council. Mayo Clinic Institutional Animal Care and
Use Committee approved all animal studies. Animal protocol
(A37708) approved by Mayo Clinic Institutional Animal Care and
Use Committee was in accordance with guidelines from the U.S.
Public Health Service Policy on Human Care and Use of
Laboratory Animals and in compliance with the U.S. Animal
Welfare Act.
Reagents
Recombinant RANKL was expressed in E. coli and purified
using GST-sepharose columns as described previously [47]. Each
batch of recombinant RANKL was tested in dose response studies
and the minimal dose that promoted maximal osteoclast
differentiation of WT marrow (typically 50 ng/ml) was used for
all of the experiments with the exception of the dose-response
studies reported here, where the maximum dose tested (100 ng/
ml) was twice the dose used for differentiation studies. MCSF was
purchased from Research and Diagnostic Systems (Minneapolis,
MN). Reagents for tartrate-resistance acid phosphatase (TRAP)
staining, Hoechst staining, and other chemicals were purchased
from Sigma–Aldrich (St. Louis, MO).
Osteoclastogenesis assays
Freshly isolated bone marrow cells were used for collection of
osteoclast precursors as we have previously reported [47]. Briefly,
tibias and femurs were removed from three WT and TIEG1
2/2
mice for each experiment (6–12 week old to 16 month old) and the
metaphyseal ends of the bones were cut and marrow cells were
flushed out using a syringe. Marrow cells were cultured in a-MEM
plus 10% fetal bovine serum (FBS) containing MCSF (25 ng/ml)
for 24 hours. Non-adherent bone marrow cells were collected,
seeded at an initial density of 4.5610
5 per well in 24-well plates,
and cultured in the presence of RANKL (50 ng/ml) and MCSF
(25 ng/ml). In parallel, cells were also cultured in the absence of
MCSF to verify no mesenchymal cell contamination. Osteoclast
precursors were fed with the same media on day 3. To evaluate the
effects of RANKL and MCSF on osteoclast differentiation,
precursors and mature osteoclasts were fixed in 1% paraformal-
dehyde and stained with Hoechst 33342 and for TRAP activity as
previously described [5].
Cell proliferation assay
WT and TIEG1
2/2 non-adherent bone marrow cells were
seeded at 1610
5 cells/well in 96-well plates and grown at 37uC for
3 h at day 0, 1, 2 and 3 of differentiation. Proliferation/survival
was measured on absorbance at 490 nm by using the non-
radioactive Cell Titer 96 Aqueous One solution cell proliferation
assay (Promega, Madison, WI.) according to the manufacturer’s
protocol. Averages from eight replicates were compared between
WT and TIEG1
2/2 osteoclasts.
Colony forming units
To determine the relative numbers of osteoclast precursors in
marrow, we analyzed the number of colony forming units
Granulocyte-Macrophage (CFU-GM) using MethoCult (Stem
Cell Technologies, Vancouver, Canada). One hundred thousand
non-adherent bone marrow cells were plated per well in 6 well
plates (4 replicates each) for 8 days. Colonies were counted using a
phase-contrast microscope.
RNA extraction and quantitative real time PCR
Total RNA was isolated from the cultured osteoclast precursors
and mature osteoclasts using TRIzol reagent (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions. RNA concentra-
tion was determined spectroscopically by measuring the absorbance
at 260 nm, and RNA purity was assessed by the 260/280 nm
the number of apoptotic osteoclasts over time are depicted. These data were obtained from three replicate wells (p,0.05) and are representative of
two separate experiments. Each experiment contained marrow cells pooled from three mice. C and D. AdTIEG1 expression effects on osteoclast
differentiation. Osteoclast precursors were cultured as in A. C represents TRAP-stained vector and AdTIEG1-infected TIEG1
2/2 osteoclasts at day 4
and D depicts the mean +/2 SD of the number of osteoclasts quantitated. These data are from three replicate wells (p,0.05) and are representative
of two separate experiments. Each experiment contained marrow cells pooled from three mice. E. AdTIEG1 expression effects on signaling. Osteoclast
precursors were cultured as in A. Day 3 osteoclast precursors and mature osteoclasts at day 4 were serum-starved and either harvested or treated
with MCSF and RANKL as indicated for five minutes. Equal amounts of total protein were analyzed by western blotting for the indicated phospho- or
total proteins. These data are representative of two separate experiments. Each experiment contained marrow cells pooled from three mice. F.
Expression of cathepsin K mRNA following restoration of TIEG1 expression. Cells were infected as in A and RNA was harvested. Samples were
analyzed by Real Time PCR for cathepsin K. Data depict mean +/2 SD and were obtained from three replicate wells (p,0.05) and are representative
of three separate experiments. G. Expression of cathepsin K protein following restoration of TIEG1 expression. Cells were infected as in A and protein
harvested 6 hours after feeding on day 3 and analyzed for cathepsin K expression levels by western blotting. These data are representative of two
separate experiments. Each experiment contained marrow cells pooled from three mice.
doi:10.1371/journal.pone.0017522.g004
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2/2 cell responses. Osteoclast precursors were transfected with accell-
siNon-targetting (siNT) or accell-siTIEG1 as detailed in the Methods section. A. Wildtype osteoclast precursors were transfected at day 2 and TIEG1
expression was monitored by Real Time PCR on day 3. In the upper panel, green fluorescence demonstrates the transfection efficiency of accell-siNT
and siTIEG1. The lower panel demonstrates the inhibition of TIEG1 expression by accell-siTIEG1 (mean +/2 SD). These data were obtained from three
replicate wells (p,0.05) and are representative of two separate experiments. Each experiment contained marrow cells pooled from three mice and
analyzed in three replicate wells. B. siNT and siTIEG1 effects on osteoclast differentiation. WT osteoclast precursors were transfected with accell-siNT
and siTIEG1 as in A and fixed and TRAP-stained on day 4. The upper panel is the quantitation of osteoclast number. The lower panel is a
representative micrograph of TRAP-stained cultures. Data are presented as the mean +/2 SD (p,0.05) and are representative of two separate
experiments. Each experiment contained marrow cells pooled from three mice and analyzed in three replicate wells. C. siNT and siTIEG1 effects on
NFATc1 phosphorylation. WT osteoclast precursors were treated as in A. Day 3 osteoclast precursors were serum-starved and either treated with
MCSF or RANKL for five minutes. Equal amounts of total protein were analyzed by western blotting for phospho- or total NFATc1. D. siNT and siTIEG1
effects on cathepsin K expression. WT osteoclast precursors were treated as in A. Day 3 osteoclast precursor cell lystaes were harvested and equal
amounts of total protein were analyzed by western blotting for cathepsin K expression. These data are representative of two separate experiments.
Each experiment contained marrow cells pooled from three mice.
doi:10.1371/journal.pone.0017522.g005
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Reaction(QPCR),firststrand cDNAwassynthesizedfrom1to2 mg
of total RNA using SuperScript II reverse transcriptase following
oligo dT priming according to the manufacturer’s instructions
(Invitrogen, Carlsbad, CA). Custom high-throughput QPCR arrays
were utilized to assay 128 genes known to be involved in
osteoclastogenesis using the ABI 7900 HT system (Applied
Biosystem, Foster City, CA). All genes were compared between
WT and TIEG
2/2 osteoclast precursors and mature osteoclasts.
Up- and down-regulated genes in TIEG1
2/2 osteoclast precursors
(n=3) relative to those obtained from WT mice (n=3) were
confirmed individually using a Bio-Rad Q-PCR (iCycler, Hercules,
CA). Sequences of primer pairs used in these QPCR experiments
are listed in Table S3. Primer pairs were designed to span introns in
order to prevent potential amplification of any contaminating
genomic DNA. Gene expression levels were calibrated using
endogenous TBP expression levels. The differences between the
mean Ct values of genes were denoted (D-Ct) and the difference
between D -Ct values of test genes and the D-Ct value of TBP was
calculated as DD -Ct. The log2(DD -Ct) was used to determine the
relative quantification value of expression and values were
compared between WT and TIEG1
2/2 cells.
Western blot analysis and antibodies
Non-adherent bone marrow cellswere cultured as described above
and subsequently lysed as previously reported [47]. Protein
concentrations were determined using the BCA protein assay kit
(Pierce, Rockford, IL). Proteins were separated using 12% SDS-
PAGE gels followed by electroblotting to Immobilon-P membranes
(Millipore, Bedford, MA) using a transfer buffer containing 50 mM
Tris, 40 mM glycine, 0.1% SDS, and 20% methanol at pH 9.2.
Membranes were blocked by incubation in 16PBS containing 5%
fat-free dry milk for 1 h at room temperature. Blots were incubated
with the following primary antibodies: AKT, pAKT, MEK1/2,
pMEK1/2,ERK,pERK1/2,Caspase-9(CellSignalingTechnology,
Boston, MA), NFATc1 (BD Pharmingen, San Jose, CA), pNFATc1,
Cathepsin K, Bcl-2 (Santa Cruz Biotechnology, Santa Cruz, CA),
and b-actin (Sigma–Aldrich). Incubation with primaryantibodies was
carried out overnight at 4uC in a dilution buffer containing 16PBS,
0.1% tween-20 and 5% fat-free dry milk. Blots were subsequently
probed with horseradish peroxidase-conjugated anti-mouse or anti-
rabbit secondary antibodies (Amersham Biosciences, Buckingham-
shire, England) diluted 1:5000 in 16PBS, 0.1% tween-20 and 5%
fat-free dry milk. Signals were visualized using the ECL Plus detection
system (Amersham Biosciences) according to the manufacturer’s
instructions.
Adenoviral infections
Mouse TIEG1 adenovirus was generated under contract by
Vector BioLabs (Philadelphia, PA). TIEG1
2/2 osteoclast precur-
sors were infected at day 2 with either adenovirus expressing
TIEG1 or vector alone and TIEG1 expression was monitored by
QPCR at day 3 and 4 to determine relative TIEG1 expression
levels. To determine optimum infection conditions, TIEG1
2/2
osteoclast precursors were infected at a range of multiplicity of
infections (0 to 50 MOI) and the MOI resulting is expression of
TIEG1 at levels similar to those observed in WT cells was selected
for use in all studies (25 MOI). The infected cells were
differentiated as described above and subsequently fixed and
stained with Hoechst and for TRAP activity. For protein and
RNA analysis, infected cells were washed twice with 16PBS and
RNA and proteins were harvested as described above.
siRNA inhibition of TIEG1 expression in wildtype bone
marrow cells
Targeted interfering RNA (Accell siRNA) for TIEG1, r(AAUG-
GAACUAAUUUCUGAA)d(TT)), was custom designed by Dar-
macon (Lafayette, CO). siRNA duplexes were transiently trans-
fected into WT osteoclast precursors using HiPerfect transfection
reagent from QIAGEN according to the manufacturer’s instruc-
tions. Transient transfection of 100 mM siTIEG1 oligonucleotides
was performed in OPTI-MEM media at day 2 and the efficiency
of TIEG1 knock-down was confirmed by QPCR as described
above. On day 3, cells were fed with a-MEM plus 10% FBS
Figure 6. Effects of loss of TIEG1 expression on genes involved in osteoclast differentiation. Osteoclast precursors from WT and TIEG1
2/2
(KO) mouse marrow were cultured as in Figure 1 for the indicated number of hours (h). Real Time PCR analysis of osteoclast differentiation marker
genes, PU-1, RANK, c-fos, and OCIL was conducted at the indicated times. These data are presented as the mean +/2 SD (p,0.05) and were obtained
from four replicate wells. Data are representative of three separate experiments.
doi:10.1371/journal.pone.0017522.g006
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evaluate the effects of siTIEG1 transfection on osteoclast
differentiation, cells were fixed in 1% paraformaldehyde and
stained with Hoechst and for TRAP activity as described
previously.
Confocal Microscopy
The localization of phospho and total NFATc1 in cultured WT
and TIEG1
2/2 precursors were examined by immuno florescence
histochemistry using a confocal microscope. Cells were fixed in 1%
paraformaldehyde for at least 30 min and washed twice with 16
PBS. Cells were permeabilized with 0.2% Triton-X in PBS for
30 min and incubated for an additional 30 min in heat-inactivated
5% FBS to block non-specific binding and subsequently incubated
with 2 ug/mL rabbit polyclonal phospho-NFATc1 or NFATc1
antibodies in PBS for an additional 60 min. Cells were washed
twice with PBS and stained with Texas Red- or FITC-conjugated
secondary IgG antibodies (Santa Cruz Biotechnology, Santa Cruz,
CA) for 60 minutes. DAPI was used for counter-staining of nuclei.
Statistics
All data are presented as mean +/2 SD. Statistical significance
was determined by 2-tailed Student’s T-test using Microsoft Excel
software.
Supporting Information
Figure S1 A. Dose-response of RANKL signaling effects on
caspase 9 expression in osteoclast precursors at day 3. The
precursor cells were treated with the indicated concentrations of
RANKL in the presence of MCSF. B. AdTIEG1 expression
effects on caspase 9 expression in osteoclast precursors. Osteoclast
precursors from TIEG1
2/2 mice were cultured and infected at
Day 2 with vector (AdVec) or TIEG1 adenovirus (AdTIEG) at an
MOI of 25.
(TIF)
Table S1 Genes associated with osteoclast fusion.
Relative expression levels are reported as mean 6 standard
deviation (SD). *The fold changes are the ratios of the mean
relative expression levels in WT over the mean relative expression
levels in KO osteoclasts (n=3).
ap,0.05.
(TIF)
Table S2 Genes not altered with the loss of TIEG1 were
associated with osteoclast fusion and Bcl2 family.
Relative expression levels are reported as mean 6 standard
Figure 7. Effects of loss of TIEG1 expression on Bcl2
expression. A. TIEG1
2/2 mouse marrow cells were cultured in the
presence of MCSF and RANKL and infected at day 2 with vector or TIEG1
adenovirus. Bcl2 expression was monitor by real time PCR at day 3.
These data were obtained from three replicate wells and are presented
as the mean +/2 SD (p,0.05). Data are representative of two separate
experiments. Each experiment contained marrow cells pooled from
three mice and analyzed in three replicate wells. B. Osteoclast
precursors were cultured and infected at day 2 as in A. Day 3 osteoclast
precursors were harvested and equal amounts of total protein were
analyzed by western blotting for Bcl2 protein. These data are
representative of two separate experiments. Each experiment con-
tained marrow cells pooled from three mice.
doi:10.1371/journal.pone.0017522.g007
Figure 8. Proposed model for TIEG1 effects on osteoclast
differentiation and survival. A. In osteoclast precursors, TIEG1
expression transiently increases expression of pro-differentiation PU.1,
leading to increased RANK expression, which induces c-Fos expression.
This, combined with suppression of the inhibitory osteoclast inhibitory
lectin (OCIL) gene, increases NFATc1 expression to enhance osteoclast
differentiation. B. Once osteoclasts mature, TIEG1 expression reduces
MEK/ERK and AKT/NFkB activation and decreases Bcl2 protein levels,
leading to osteoclast apoptosis.
doi:10.1371/journal.pone.0017522.g008
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relative expression levels in WT over the mean relative expression
levels in KO osteoclasts (n=3).
(TIF)
Table S3 Oligonucleotide primer pairs (Sense and
Antisense) used for Q-PCR.
(TIF)
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